LAP degradation product reflects plasma kallikrein-dependent TGF-β activation in patients with hepatic fibrosis
SpringerPlus volume 3, Article number: 221 (2014)
Byproducts of cytokine activation are sometimes useful as surrogate biomarkers for monitoring cytokine generation in patients. Transforming growth factor (TGF)-β plays a pivotal role in pathogenesis of hepatic fibrosis. TGF-β is produced as part of an inactive latent complex, in which the cytokine is trapped by its propeptide, the latency-associated protein (LAP). Therefore, to exert its biological activity, TGF-β must be released from the latent complex. Several proteases activate latent TGF-β by cutting LAP. We previously reported that Camostat Mesilate, a broad spectrum protease inhibitor, which is especially potent at inhibiting plasma kallikrein (PLK), prevented liver fibrosis in the porcine serum-induced liver fibrosis model in rats. We suggested that PLK may work as an activator of latent TGF-β during the pathogenesis of liver diseases in the animal models. However, it remained to be elucidated whether this activation mechanism also functions in fibrotic liver in patients.
Here, we report that PLK cleaves LAP between R58 and L59 residues. We have produced monoclonal antibodies against two degradation products of LAP (LAP-DP) by PLK, and we have used these specific antibodies to immunostain LAP-DP in liver tissues from both fibrotic animals and patients.
The N-terminal side LAP-DP ending at R58 (R58 LAP-DP) was detected in liver tissues, while the C-terminal side LAP-DP beginning at L59 (L59 LAP-DP) was not detectable. The R58 LAP-DP was seen mostly in α-smooth muscle actin-positive activated stellate cells.
These data suggest for the first time that the occurrence of a PLK-dependent TGF-β activation reaction in patients and indicates that the LAP-DP may be useful as a surrogate marker reflecting PLK-dependent TGF-β activation in fibrotic liver both in animal models and in patients.
Liver fibrosis is characterized as the pathological deposition of excessive extracellular matrix (ECM), which finally causes hepatic dysfunction (Bataller and Brenner 2005). A key driver of fibrosis is the 25 kD homodimeric cytokine, transforming growth factor (TGF)-β (Dooley and ten Dijke 2012). TGF-β is produced as a latent complex; therefore, an essential step for controlling TGF-β activity is its activation, a process in which biologically active TGF-β is released from the latent complex (Figure 1a) (Dabovic and Rifkin 2008).
TGF-β1 is produced as a 390 amino acid precursor protein consisting of a signal peptide of 29 amino acids, an N-terminal pro-region called latency-associated protein (LAP), and a C-terminal region that becomes the active TGF-β1 molecule, and each region dimerized through S-S bonds. After processing by cleavage at R278-A279 by a furin-like protease, the LAP non-covalently binds the mature TGF-β1, forming small latent complex (SLC) and preventing active TGF-β1 from binding its cognate receptors (Figure 1a). The active TGF-β1 and the LAP homodimer are 25 kD and 75 kD, respectively. The SLC is S-S bonded to another gene product, the latent TGF-β binding protein (LTBP), via C33 residues, forming the large latent complex (LLC). This complex can be sequestered in the ECM (Figure 1a) (Breitkopf et al. 2001). LTBP is a member of an ECM protein family, fibrillin (Zilberberg et al. 2012).
Several molecules are known to activate TGF-β1 in animal models. These include integrins (Nishimura 2009; Henderson et al. 2013), thrombospondin (Ribeiro et al. 1999), and proteases, such as matrix metalloproteinases (MMPs) (Yu and Stamenkovic 2000) and serine proteases (Jenkins 2008). Lyons R.M. et al. first reported that plasmin digests LAP and activates TGF-β1 in vitro (Lyons et al. 1990). Using a protease inhibitor, Camostat Mesilate, we previously demonstrated that plasma kallikrein (PLK) is involved in the TGF-β1 activation associated with liver fibrosis and impaired liver regeneration in animal models (Okuno et al. 2001; Akita et al. 2002). However, it remained to be elucidated whether PLK-dependent TGF-β1 activation also occurs during the pathogenesis of liver fibrosis in patients.
In this paper, we describe successful experiments aimed at generating specific antibodies against the two degradation products of LAP (LAP-DP) produced after PLK digestion, and the use of these antibodies to stain the LAP-DP in patient livers, thereby providing evidence of PLK-dependent TGF-β1 activation in human hepatic fibrosis. The results demonstrate the potential utility of the LAP-DP as a surrogate marker for PLK-dependent activation of TGF-β1 in the liver.
Identification of LAP cleavage sites during proteolytic activation of latent TGF-β1
PLK primarily cleaved recombinant human LAP β1 (rhLAP β1) between R58 and L59 residues (Figure 1b). Further incubation resulted in cleavage between R267and A268 residues.
Preparation of specific antibodies that recognize LAP neo-epitopes formed by PLK during TGF-β1 activation
Based on the amino acid sequences of PLK cleavage site, we prepared monoclonal antibodies that recognized the neo-epitopes formed within LAP during PLK-dependent TGF-β1 activation (Figure 1). The antibodies against the neo-C-terminal end of the PLK-cleaved N-terminal side LAP-DP ending at R58 (referred as R58 LAP-DP) and the neo-N-terminal end of the PLK-cleaved C-terminal side LAP-DP beginning from L59 (referred as L59 LAP-DP) were named R58 and L59 antibodies, respectively. Figure 2 shows Western blots using Glutathione-S-transferase (GST) fused-recombinant human latent TGF-β1 (GST-rhLTGF-β1) or rhLAP β1 (schematic structures are illustrated in panel a) to examine the specificities of R58 and L59 antibodies. The R58 antibody recognized only GST-fused R58 LAP-DP around 30 kD (panel b, lane 2), and the L59 antibody recognized the 29 kD of L59 LAP-DP (panel d, lane 2). However, both R58 and L59 antibodies did not recognize uncleaved GST-rhLTGF-β1 and rhLAP β1 (panels b and d, lane 1) that were detectable by the monoclonal anti-LAP antibody recognizing N-terminal side LAP-DP (panel c) or the polyclonal anti-LAP antibody recognizing C-terminal side LAP-DP (panel e). Moreover, neither R58 nor L59 antibodies detected LAP-DPs generated by plasmin (PLN) digestion (panels b and d, lane 4) These data demonstrated that the anti-LAP antibodies recognize both LAP and PLK-cleaved LAP-DP, while the R58 and L59 antibodies specifically recognize only the respective LAP-DP. There are three isoforms of pro-TGF-βs. Amino acid sequences between E47 and L59 residues in LAP are identical between TGF-β1 and TGF-β3 (Additional file 1: Figure S1). Hence, we checked whether R58 antibody can recognize TGF-β3 LAP-DP as well as TGF-β1 LAP. As shown in Additional file 2: Figure S2, R58 antibody recognized PLK-digested TGF-β1 and β3 LAP peptide, but not non-digested and PLN-digested TGF-β1 and β3 LAP peptides (upper and lower lane, respectively) nor TGF-β2 LAP peptide, which does not have P1 site R58 residue, irrespective of PLK or PLN digestion (middle lane). These data suggested that R58 and L59 antibodies are promising tools to monitor cleavage of LAP by PLK, in other words, both R58 and L59 LAP-DPs can be footprints of PLK-dependent TGF-β1 as well as TGF-β3 activation.
Immunohistochemistry of murine fibrotic liver using R58 antibodies
Because LAP may be S-S bonded to LTBP present in the ECM, we expected that the R58 LAP-DP would remain within fibrotic tissues after cleavage of LAP by PLK. We tested this possibility in fibrotic livers from the carbon tetrachloride (CCl4)-treated mice and bile duct ligated (BDL)-mice using R58 antibody. As shown in Figure 3, at 12 weeks after initiating CCl4 treatment, CCl4-treated mice displayed hepatocellular injury around the lobes (panel a) and bridging fibrosis from central veins to portal areas (panel b). The R58 LAP-DP was detectable and increased in CCl4-treated mice (panel c), especially along fibrotic areas in CCl4-treated mice compared with olive oil treated control mice. Positive area rates were increased 5-folds as written underneath panels c and f. Small positive spots seen in the control section were non-specific staining of mostly erythrocytes (panel f). Similar results were obtained from BDL mice (Figure 4). BDL mice often exhibited granulomatous lesions (panel a), in which fibroblastic cells infiltrated and started ECM production (panel b). The R58 LAP-DP was detected in granulomatous lesions prior to Sirius red positivity, namely before collagen accumulation (arrowheads in panel c). Positive areas were increased 3-folds as written underneath panels c and f. Signals from R58 LAP-DP was absorbed by pre-incubation of R58 antibody with antigen-peptides, and non-immune mouse IgG failed to yield a signal (Figure 5a-c), indicating that the signals were specific to R58 LAP-DP. We were unable to stain the L59 LAP-DP with L59 antibody although various antigen unmasking procedures were treated (Figure 5d). In, Figure 6, non-parenchymal regions were recognized by antibody R58 (red arrowheads in upper panels), and mostly overlapped with α-smooth muscle actin (αSMA)-positive activated hepatic stellate cells (HSCs) (red arrowheads in second row panels), but not with CD31-positive liver sinusoidal endothelial cells (third row panels) nor with F4/80-positive Kupffer cells (hepatic macrophages) (lower panels). Activated HSCs in the fibrotic liver were stained strongly with anti-pSmad3C antibody compared to olive oil-treated control mice (arrowheads in Figure 7, left panel), suggesting that TGF-β signaling was provoked. These data suggest that PLK-dependent TGF-β1/3 activation was induced in murine liver fibrosis models and that R58 LAP-DP, but not L59 LAP-DP, can be a footprint of the generation of active TGF-β1/3 in liver tissue.
Immunohistochemistry of fibrotic liver tissues from patients using R58 antibody
Finally, we evaluated human liver sections with the R58 antibody to determine if PLK-dependent TGF-β1/3 activation occurs in clinical liver diseases. Fibrotic liver tissues from patients with viral hepatitis categorized as A1F2 and A2F2 were stained robustly with the R58 antibody (Figure 8a). As with animal models, no signals could be detected by L59 antibody (Figure 8b). In peri-sinusoidal and fibrotic regions around the hepatic lobes, R58 LAP-DP was present in non-parenchymal cells, mainly in αSMA-positive HSC (arrows in Figure 8c). R58 signals could be detected along fibrous septa, implying that R58 LAP-DP accumulated within the ECM upon TGF-β1/3 activation. A similar staining with the R58 antibody was observed in patients with non-viral hepatitis, such as autoimmune hepatitis (AIH) and non-alcoholic steatohepatitis (NASH) (Figure 8d). These data clearly indicated that PLK-dependent TGF-β1/3 activation is induced during the pathogenesis of liver fibrosis in patients with a range of liver diseases, and that PLK-cleaved R58 LAP-DP might serve as a novel surrogate biomarker of TGF-β1/3 activation and its associated fibrosis in patients.
An important step to control biological activity of TGF-β is its activation referred as “TGF-β activation.” Proteolytic activation of latent TGF-β1 was first described in 1988 (Lyons et al. 1988) and was demonstrated in hepatic stellate cells during the pathogenesis of liver fibrosis and/or impaired liver regeneration in animal models (Okuno et al. 2001; Akita et al. 2002). Although we described PLK-dependent TGF-β activation in rodent models of the liver diseases, it remained to be elucidated whether this mechanism is also effective in patients.
Here, we have identified PLK cleavage site within the LAP of latent TGF-β1, and have generated antibodies that specifically recognize the neo C- and N-termini of LAP-DPs (R58 and L59 antibodies, respectively) (Figure 1). These antibodies may be powerful tools to detect the footprints of latent TGF-β1 activation. Notably, we successfully used the antibodies to detect LAP-DP generated during TGF-β1 activation in human samples. For the first time, we demonstrated that the PLK-dependent activation of latent TGF-β1 is associated with human hepatic diseases with the use of the R58 antibody. This technique can be generally applied to measure activation of other cytokines, in which by-products corresponding to the LAP-DP are generated.
The primary cleavage site of LAP by PLK was between R58-L59 (Figure 1b). Interestingly, the PLK cleavage site is proximal with the putative binding site for thrombospondin (L54SKL57) (Ribeiro et al. 1999). This suggests that the region containing L54SKLRL59 is important for maintaining TGF-β1 latency. Consistent with this idea, it was recently revealed that the active TGF-β1 molecule is associated with this region based both on mutational analysis (Walton et al. 2010) and the crystal structure of porcine latent TGF-β1 (Shi et al. 2011). Specifically, this sequence is located near the C-terminal end of α1 helix of LAP and hydrophobic residues containing L54, L57, and L59, which are present along the inner face of the α1 helix, interact with W308/W310 and with aliphatic side chains of active TGF-β1. The α1 helix is predicted to play a role of a ‘straitjacket’ for active TGF-β1 (Walton et al. 2010). The K56 fastens the C-terminal end of the α1 helix in cooperation with Y74-A76, and moreover associates S380 via hydrogen bonding (Shi et al. 2011). The P1 site amino acids (R58) are located on the outer face of LAP, so PLK cleavage site should be highly accessible. Proteolytic cleavage within this region is likely to cause a conformational change of the LAP, resulting in a loss of its association with the active TGF-β1 molecule and release of active TGF-β1 molecule from the latent complex.
In Figure 2, we made monoclonal antibodies against both N- and C-terminal side LAP-DP (R58/L59 LAP-DP) and checked their reaction specificities by western blotting. R58/L59 antibodies detected neither uncleaved LAP nor PLN-cleaved LAP-DP, and specifically recognized only PLK-cleaved LAP-DP, whereas anti-LAP antibodies recognized both uncleaved and PLK-cleaved LAP-DP. In Figure 2c, lane 4, we failed to detect N-terminal side LAP-DP made by PLN digestion with monoclonal anti-LAP antibody that nicely detected N-terminal side LAP-DP made by PLK digestion. We speculate that the epitope recognized by this anti-LAP antibody would be lost by PLN digestion.
Three isoforms of proTGF-β (β1-β3) have been characterized (Massague 1990), and LAP domains of different isoforms share 28-45% identity. TGF-β2 LAP does not have the sequences cleaved by PLK, whereas TGF-β3 LAP has the same sequences as TGF-β1 LAP. Our results indicated that PLK can cleave TGF-β3 LAP, and that their degradation products were detectable by R58 antibody. Because TGF-β3 expression is reported to be very weak in the liver (De Bleser et al. 1997), we think it is likely that the R58 LAP-DP we detected is derived mainly from TGF-β1 LAP, but partly from TGF-β3 LAP.
We also successfully detected PLK-cleaved R58 LAP-DP using the R58 antibody in fibrotic mice, suggesting that PLK dependent TGF-β1/3 activation was at least involved in murine hepatic fibrosis and that PLK-cleaved LAP-DP might be a marker for liver fibrosis. Our previous study demonstrated that PLN also plays an important role in liver fibrosis in the rat porcine serum model (Okuno et al. 2001), therefore we are now using the same strategy to produce antibodies that recognize PLN-cleaved LAP-DP. Similar to murine models, R58 LAP-DP was observed in patients suffering from hepatic diseases. Fibrous septa were obviously stained by the R58 antibody, indicating that R58 LAP-DP was generated at the site of the TGF-β1/3 activation and remained there. The intensity of R58 signals did not correlate with the severity of hepatic inflammation and fibrosis, so future studies will assess what drives increased R58 expression in vivo.
In contrast to the R58 antibody, we obtained essentially no positive signals with L59 antibody staining in both rodent and human samples. This suggests that C-terminal side L59 LAP-DP might be released after proteolytic digestion. Recently, we established an ELISA using the L59 antibody and successfully detected PLK-cleaved L59 LAP-DP generated in in vitro reactions. Currently, we are examining if we can detect L59 LAP-DP in plasma from animal models and patients, and if so, what is the clinical relevance of these values in liver diseases.
Integrins are known to activate TGF-β1, and it is reported that several subtypes of integrin, for example, αvβ6, are related to hepatic fibrosis in both animal models and patients (Patsenker et al. 2008; Henderson and Sheppard 2013; Allison 2012). Because integrins, which are anchored to the cell membrane, stretch the LAP by interacting via the RGD motifs to release active TGF-β1, the LAP DP is not produced (Wipff et al. 2007). Therefore compared to integrins, PLK-cleaved R58 LAP-DP will serve as a more direct biomarker for TGF-β1 activation and following liver fibrosis.
Du X et al. showed that MMP-2 is related to renal fibrosis (Du et al. 2012). Several MMPs are also known to activate latent TGF-β1 (Yu and Stamenkovic 2000), although their cleavage sites within LAP have not been determined. Therefore, we are expanding our current method to detect MMP-mediated TGF-β1 activation in the kidney.
In summary, we demonstrate here 1) PLK cleaves LAP between R58 and L59 residues, 2) PLK-dependent TGF-β activation occurs in human hepatic fibrosis, and 3) PLK-cleaved LAP-DP is the potential surrogate marker for proteolytic TGF-β1/3 activation and in turn fibrogenesis in the liver.
Recombinant human TGF-β1 LAP (rhLAP β1) and both monoclonal and polyclonal anti-human LAP β1 antibodies (MAB246 and AF246, respectively) were purchased from R&D Systems (Minneapolis, MN). Human PLK was from CalBiochem (San Diego, CA). Anti-αSMA antibody were purchased from DAKO (Glostrup, DK). Anti-CD31 antibody was from dianova GmbH (Hamburg, DE). Anti-F4/80 antibody was from AbD serotec, LLC (Oxford, UK). Anti-pSmad3C polyclonal antibody was a kind gift from Dr. Matsuzaki (Kansai Med. Univ., Japan). GST-rhLTGF-β1 protein was prepared as described follows. A plasmid encoding GST-rhLTGF-β1 was constructed by inserting a human TGF-β1 cDNA into the pGEX-6P-1 vector (GE Healthcare, Buckinghamshire, UK), and protein expressed in E. coli. BL21 (Stratagene, La Jolla, CA) and purified using Glutathione Sepharose (GE Healthcare).
Determination of the cleavage sites within LAP by PLK
To identify the cleavage site in LAP during latent TGF-β1 activation by PLK, rhLAP β1 was incubated with PLK. After digestion, the resultant fragments were separated by SDS-polyacrylamide gel electrophoresis, and the N-terminal sequence of each LAP-DP was determined using a pulsed liquid protein sequencer Precise 494cLC (Hayashi et al. 2008).
Preparation of R58 and L59 monoclonal antibodies against neo C- and N-termini of LAP-DPs generated by PLK
Murine R58 and L59 monoclonal antibodies were generated against an 8 amino acid peptide, ending at R58 and plus a CG linker sequence at its N-terminus [CGGQILSKLR (Figure 1b)] and an 11 amino acid peptide, beginning from L59 and plus a GGC linker sequence [LASPPSQGEVPGGC (Figure 1b)]. BALB/c mice purchased from Charles River Laboratories Japan, Inc. (Kanagawa, Japan) were immunized with 50 μg of the antigen peptides. Once an appropriate titer had been achieved, fusion was performed using a protocol adapted from Lane et al. (Lane et al. 1986). Positive clones, which reacted to the BSA-conjugated antigen peptide, but not to the terminus-modified antigen peptide (the C-termini were amidated for R58 antibody, while the N termini were acetylated for L59 antibody production), were selected. The antibodies were purified through the Protein G column (GE Healthcare).
SDS-PAGE and Western blot analysis
GST-rhLTGF-β1 as well as rhLAP β1 were digested by co- incubation with PLK or PLK at 37°C for 45 min. Thereafter, equal amounts of samples containing either 50 ng of GST-rhLTGF-β1 or 500 ng of rhLAP β1 were subjected to each lane in SDS-PAGE under reducing conditions, followed by transfer onto PVDF membrane (Millipore, Bedford, MA). Western blot analyses were performed using either monoclonal R58 and L59 antibodies (2 μg/ml) plus HRP-conjugated anti-mouse antibodies (1:5,000) (Jackson Immuno Research Laboratories, Inc., West Grove, PA) and reprobed either with monoclonal or polyclonal anti-LAP antibodies. The bands were visualized by a Western Blotting Substrate Plus purchased from Thermo Scientific (Rockford, IL).
Male C57BL/6 mice were purchased from Japan SLC Inc. (Shizuoka, Japan). All animals were maintained on a 12 hour light/12 hour dark cycle. Food and water were available ad libitum. All animal experiments were performed in accordance with protocols approved by the RIKEN Institutional Animal Use and Care Administrative Advisory Committee. For the CCl4-induced liver fibrosis model, mice were injected intramuscularly with 50% CCl4 (CCl4: olive oil = 1:1, 2 ml/kg) twice a week for 12 weeks. Control animals were injected with the same volume of olive oil. Mice were sacrificed one week after the last CCl4 injection. For the BDL model, ligation of the common bile duct was performed according to Arias et al. (Arias et al. 2003). Sham-operated mice were treated in the same manner except that the bile duct was not ligated. The animals were sacrificed at 14 days after operation.
The study was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee for Biomedical Research of the Jikei University School of Medicine and RIKEN Institute Research Ethics Committee. All patients had signed a written informed consent prior to study. Liver biopsy samples were taken from patients suffering with cirrhotic liver diseases due to infection with types B and/or C hepatitis virus, AIH and NASH.
The stage of fibrosis and the grade of inflammatory activity were classified according to the METAVIR score (Bedossa and Poynard 1996).
Staining of liver tissue sections
Animal tissue specimens were fixed in 4% paraformaldehyde, and human biopsied samples were fixed in 10% neutral buffered formalin. They were all embedded in paraffin. Sections (4 μm thickness) were stained by Hematoxylin and Eosin (HE), as well as 0.1% picro-sirius red solution for diagnostic purposes. For immunostaining of the LAP-DP, antigens were retrieved by microwave in citrate buffer (pH 6), and thereafter sections were incubated in 0.3% H2O2/methanol for 30 min to block endogenous peroxidases, followed by incubation in phosphate buffered saline with 0.1% Tween 20 (PBST) containing 5% skim milk for 30 min to prevent nonspecific binding. Serial sections were then incubated with R58 (1 μg/ml) or L59 (1 μg/ml) overnight at 4°C. As negative controls, slides were incubated with nonimmune IgG under the same conditions. EnVision/HRP (DAKO) was used as the second antibody. Serial sections were also immunostained with anti-αSMA (diluted with 1:100, an activated HSC marker), anti-CD31 (5 μg/ml, a liver sinusoidal endothelial cell marker), and anti-F4/80 (5 μg/ml, a Kupffer cell marker) antibodies. The sections were counterstained with Hematoxylin. Fibrosis was detected using Sirius red as previously described (Junqueira et al. 1979). Both fibrotic areas and R58 positive areas were measured in each of three fields of five independent sections by WinROOF image analysis software.
Four μm of liver sections were deparaffinized and heated to 121°C in citrate buffer (pH6) by an autoclave for 10 min for antigen retrieval. After blocking with 3% BSA/10% normal goat serum/0.1 M glycine/PBST for 30 min, the sections were incubated with both anti-pSmad3C (2 μg/ml) and anti-αSMA (1:100) antibodies overnight at 4°C, followed by incubation with both Alexa Fluor 488 anti-rabbit IgG and Alexa Fluor 555 anti-mouse IgG (1:1000; red; Life Technologies, Carlsbad, CA) for 2 hours at room temperature. Thereafter, the sections were incubated with Hoechst 33258 (1:5000, DOJINDO Laboratories, Kumamoto, Japan) for 10 min at room temperature, and were mounted with Fluoromount (Diagnostic BioSystems, Pleasanton, CA). Image data were acquired on a Zeiss LSM 700 laser scanning confocal microscopy.
Quantitative data are shown as mean ± SE. The two-sample Wilcoxon rank-sum test was employed to evaluate difference between two groups. A p-value < 0.01 was considered as statistically significant.
Transforming growth factor-β
Small latent complex
Latent TGF-β binding protein
Large latent complex
Degradation product of LAP
- rhLAP β1:
Recombinant human LAP β1
- R58 LAP-DP:
PLK-cleaved N-terminal side LAP-DP ending at R58
- L59 LAP-DP:
PLK-cleaved C-terminal side LAP-DP beginning from L59
Bile duct ligation
α-smooth muscle actin
Hepatic stellate cell
Hematoxylin and Eosin
Phosphate buffered saline with 0.1% Tween 20.
Akita K, Okuno M, Enya M, Imai S, Moriwaki H, Kawada N, Suzuki Y, Kojima S: Impaired liver regeneration in mice by lipopolysaccharide via TNF-alpha/kallikrein-mediated activation of latent TGF-beta. Gastroenterology 2002, 123(1):352-364. 10.1053/gast.2002.34234
Allison M: Stromedix acquisition signals growing interest in fibrosis. Nat Biotechnol 2012, 30(5):375-376. doi:10.1038/nbt0512-375 10.1038/nbt0512-375
Arias M, Sauer-Lehnen S, Treptau J, Janoschek N, Theuerkauf I, Buettner R, Gressner AM, Weiskirchen R: Adenoviral expression of a transforming growth factor-beta1 antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats. BMC Gastroenterol 2003, 3: 29. doi:10.1186/1471-230X-3-29 10.1186/1471-230X-3-29
Bataller R, Brenner DA: Liver fibrosis. J Clin Invest 2005, 115(2):209-218. doi:10.1172/JCI24282 10.1172/JCI24282
Bedossa P, Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24(2):289-293. doi:10.1002/hep.510240201 10.1002/hep.510240201
Breitkopf K, Lahme B, Tag CG, Gressner AM: Expression and matrix deposition of latent transforming growth factor beta binding proteins in normal and fibrotic rat liver and transdifferentiating hepatic stellate cells in culture. Hepatology 2001, 33(2):387-396. doi:10.1053/jhep.2001.21996 10.1053/jhep.2001.21996
Dabovic B, Rifkin DB: TGF-β Bioavailability: Latency, Targeting, and Activation. In The TGF-β Family. Edited by: Derynck R, Miyazono K. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; 2008:179-202.
De Bleser PJ, Niki T, Rogiers V, Geerts A: Transforming growth factor-beta gene expression in normal and fibrotic rat liver. J Hepatol 1997, 26(4):886-893. 10.1016/S0168-8278(97)80257-7
Dooley S, ten Dijke P: TGF-beta in progression of liver disease. Cell Tissue Res 2012, 347(1):245-256. doi:10.1007/s00441-011-1246-y 10.1007/s00441-011-1246-y
Du X, Shimizu A, Masuda Y, Kuwahara N, Arai T, Kataoka M, Uchiyama M, Kaneko T, Akimoto T, Iino Y, Fukuda Y: Involvement of matrix metalloproteinase-2 in the development of renal interstitial fibrosis in mouse obstructive nephropathy. Lab Invest 2012, 92(8):1149-1160. doi:10.1038/labinvest.2012.68 10.1038/labinvest.2012.68
Hayashi M, Tamura Y, Dohmae N, Kojima S, Shimonaka M: Plasminogen N-terminal activation peptide modulates the activity of angiostatin-related peptides on endothelial cell proliferation and migration. Biochem Biophys Res Commun 2008, 369(2):635-640. doi:10.1016/j.bbrc.2008.02.050 10.1016/j.bbrc.2008.02.050
Henderson NC, Sheppard D: Integrin-mediated regulation of TGFbeta in fibrosis. Biochim Biophys Acta 2013, 1832(7):891-896. doi:10.1016/j.bbadis.2012.10.005 10.1016/j.bbadis.2012.10.005
Henderson NC, Arnold TD, Katamura Y, Giacomini MM, Rodriguez JD, McCarty JH, Pellicoro A, Raschperger E, Betsholtz C, Ruminski PG, Griggs DW, Prinsen MJ, Maher JJ, Iredale JP, Lacy-Hulbert A, Adams RH, Sheppard D: Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med 2013, 19(12):1617-1624. doi:10.1038/nm.3282 10.1038/nm.3282
Jenkins G: The role of proteases in transforming growth factor-beta activation. Int J Biochem Cell Biol 2008, 40(6–7):1068-1078. doi:10.1016/j.biocel.2007.11.026
Junqueira LC, Bignolas G, Brentani RR: Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem J 1979, 11(4):447-455. 10.1007/BF01002772
Lane RD, Crissman RS, Ginn S: High efficiency fusion procedure for producing monoclonal antibodies against weak immunogens. Methods Enzymol 1986, 121: 183-192.
Lyons RM, Keski-Oja J, Moses HL: Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J Cell Biol 1988, 106(5):1659-1665. 10.1083/jcb.106.5.1659
Lyons RM, Gentry LE, Purchio AF, Moses HL: Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol 1990, 110(4):1361-1367. 10.1083/jcb.110.4.1361
Massague J: The transforming growth factor-beta family. Annu Rev Cell Biol 1990, 6: 597-641. doi:10.1146/annurev.cb.06.110190.003121 10.1146/annurev.cb.06.110190.003121
Nishimura SL: Integrin-mediated transforming growth factor-beta activation, a potential therapeutic target in fibrogenic disorders. Am J Pathol 2009, 175(4):1362-1370. doi:10.2353/ajpath.2009.090393 10.2353/ajpath.2009.090393
Okuno M, Akita K, Moriwaki H, Kawada N, Ikeda K, Kaneda K, Suzuki Y, Kojima S: Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology 2001, 120(7):1784-1800. 10.1053/gast.2001.24832
Patsenker E, Popov Y, Stickel F, Jonczyk A, Goodman SL, Schuppan D: Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology 2008, 135(2):660-670. doi:10.1053/j.gastro.2008.04.009 10.1053/j.gastro.2008.04.009
Ribeiro SM, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ullrich JE: The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta. J Biol Chem 1999, 274(19):13586-13593. 10.1074/jbc.274.19.13586
Shi M, Zhu J, Wang R, Chen X, Mi L, Walz T, Springer TA: Latent TGF-beta structure and activation. Nature 2011, 474(7351):343-349. doi:10.1038/nature10152 10.1038/nature10152
Walton KL, Makanji Y, Chen J, Wilce MC, Chan KL, Robertson DM, Harrison CA: Two distinct regions of latency-associated peptide coordinate stability of the latent transforming growth factor-beta1 complex. J Biol Chem 2010, 285(22):17029-17037. doi:10.1074/jbc.M110.110288 10.1074/jbc.M110.110288
Wipff PJ, Rifkin DB, Meister JJ, Hinz B: Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J Cell Biol 2007, 179(6):1311-1323. doi:10.1083/jcb.200704042 10.1083/jcb.200704042
Yu Q, Stamenkovic I: Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000, 14(2):163-176.
Zilberberg L, Todorovic V, Dabovic B, Horiguchi M, Courousse T, Sakai LY, Rifkin DB: Specificity of latent TGF-beta binding protein (LTBP) incorporation into matrix: role of fibrillins and fibronectin. J Cell Physiol 2012, 227(12):3828-3836. doi:10.1002/jcp.24094 10.1002/jcp.24094
We thank Dr. Matsuzaki (Kansai Medical University) for providing phospho-Smad3C antibodies. This work was supported partly by the Program for Promotion of Fundamental Studies in Health Science of National Institute of Biomedical Innovation (NIBL) and a grant from the “Chemical Genomics Research program” from RIKEN (to S.K.), the Uehara Memorial Foundation, Japan (to S.K.), the Research on the Innovative Development and the Practical Application of New Drugs for Hepatitis B (Principal investigator: Soichi Kojima; H24-B Drug Discovery-Hepatitis-General-003) provided by the Ministry of Health, Labor and Welfare of Japan, from the NIDDK, RO1DK56621 (to S.L.F.) and NCI, RO1 CA03482 and NIAMS, PPG AR049698 (to D.B.R.).
The authors declare that they have no competing interests. Although Shinji Ogawa is an employee of Pfizer Inc., this did not affect the experimental design or interpretation of the results.
HM and KA performed experiments. HM also wrote the manuscript. KW, OS, and IOS contributed to the production of the antibodies. MT and NK collected biopsied human liver samples and discussed the staining data. DN performed the protein sequences for determination of PLK cleavage sites within LAP. FSL, RDB, and KS planned the research. KS supervised the entire project. All authors read and approved the final manuscript.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Hara, M., Kirita, A., Kondo, W. et al. LAP degradation product reflects plasma kallikrein-dependent TGF-β activation in patients with hepatic fibrosis. SpringerPlus 3, 221 (2014). https://doi.org/10.1186/2193-1801-3-221